Launch · Healthcare & Life Sciences

Temple publishes first validation study of wearable

By Startup Enthusiast · 7 September 2026

What they do

Temple makes a wearable device that tracks brain blood flow from the side of the head

It released a preprint study showing its metric correlates with Doppler readings in 20 adults

The company raised about ₹493 crore earlier in 2026 and plans to ship devices by year-end

Temple released its first validation study of its wearable device.
The study was published as a preprint and submitted for peer review.
It involved 23 healthy adults; data from 20 participants were analysed.
Temple's brain flow metric showed a median within-subject correlation of ~0.8 with middle cerebral artery blood-flow velocity measured by Doppler ultrasound.
During a postural test, heart rate declined while cerebral blood-flow velocity increased; Temple's metric moved in the same direction as the Doppler reading.
The study does not establish the ability to measure absolute cerebral blood flow or diagnose medical conditions.
Further validation studies of Brain Flow and Entropy metrics are underway.
Temple is offering device loans to qualified researchers.

This is Temple's first public evidence that its wearable can track brain blood flow.
The study provides initial validation but is not yet peer-reviewed.
Temple raised ~₹493 crore earlier in 2026 from Peak XV Partners, Steadview Capital, NK Squared, and Deepinder Goyal.
The company's valuation nearly doubled to $375 million as part of an ESOP liquidity programme for early employees.
Temple also acquired London-based longevity medicine practice Longevous for an undisclosed amount.

Temple is developing a wearable device that continuously tracks signals associated with cerebral blood flow.
It measures 'brain flow' from the side of the head.
The company reduced the wearable size to less than half of the earlier version.
Temple is preparing to open preorders and expects to begin shipping the device before the end of 2026.
It raised ~₹493 crore earlier in 2026 at a valuation of ~₹1,700 crore (~$204 million).
The valuation later nearly doubled to $375 million as part of an ESOP liquidity programme.
Temple acquired London-based longevity medicine practice Longevous for an undisclosed amount.

Further validation studies of Brain Flow and Entropy metrics are underway.
Temple is offering device loans to qualified researchers.
The company is preparing to open preorders and expects to begin shipping the device before the end of 2026.

Product: A brain-monitoring wearable device designed to track health metrics.
Customers: Individual consumers interested in health and brain-monitoring technology.
How it makes money: Direct sale of wearable hardware devices to consumers.
What sets it apart: Claims to be the smallest wearable device on the market.
Operations: Manufacturing is outsourced to partners like Zetwerk and Ethereal Machines.